OSE Immunotherapeutics - FDA support received for Tedopi Phase III trial
OSE has announced that it has received positive recommendations from its ‘type C’ meeting with the FDA for the planned confirmatory Phase III trial...
286 Views
OSE Immunotherapeutics - Introducing its fifth clinical asset
OSE Immunotherapeutics has announced the first patient dosing in a new trial, marking the introduction of the company’s fifth asset to clinical...
673 Views
OSE Immunotherapeutics - €10m funding secures runway to Q323
OSE Immunotherapeutics (OSE) has announced the receipt of €10m in financing from the European Investment Bank (EIB), which we estimate will secure...
676 Views
OSE Immunotherapeutics - OSE-127 encouraging preclinical data in ALL
OSE Immunotherapeutics (OSE) has reported positive preclinical efficacy data for its novel monoclonal antibody therapy OSE-127 in B- and T-cell...
696 Views
OSE Immunotherapeutics - OSE-127 Phase II study enrolment completed
OSE Immunotherapeutics (OSE) completed patient recruitment in its Phase IIa study (NCT04605978) investigating its monoclonal antibody therapy,...
302 Views